UroGen Pharma (URGN) 10-K 18 Mar 21 2020 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2020	Feb. 26, 2021	Jun. 30, 2020
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	FY
Title of 12(b) Security	Ordinary Shares, par value NIS 0.01 per share
Trading Symbol	URGN
Security Exchange Name	NASDAQ
Entity Registrant Name	UROGEN PHARMA LTD.
Entity Central Index Key	0001668243
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Shell Company	false
Entity Emerging Growth Company	false
Entity Common Stock, Shares Outstanding		22,272,848
Entity Public Float			$ 525.4
Entity Interactive Data Current	Yes
Document Annual Report	true
Document Transition Report	false
Entity File Number	001-38079
Entity Incorporation, State or Country Code	L3
Entity Tax Identification Number	98-1460746
Entity Address, Address Line One	400 Alexander Park
Entity Address, City or Town	Princeton
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	08540
City Area Code	646
Local Phone Number	768-9780
ICFR Auditor Attestation Flag	false
Documents Incorporated by Reference	DOCUMENTS INCORPORATED BY REFERENCE Document Description 10-K Part Portions of the registrant’s definitive proxy statement to be filed with the Securities and Exchange Commission pursuant to Regulation 14A within 120 days after the registrant’s fiscal year ended December 31, 2020 are incorporated by reference into Part III of this report. III

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 52,864	$ 49,688
Marketable securities	49,154	97,389
Restricted cash	1,226	523
Accounts receivable	7,047
Inventory	1,964
Prepaid expenses and other current assets	3,364	1,034
Total current assets	115,619	148,634
Non-current assets:
Property and equipment, net	2,046	977
Restricted deposit	223	223
Right of use asset	2,158	3,735
Marketable securities	1,893	48,555
Other non-current assets	66	264
Total Assets	122,005	202,388
Current liabilities:
Accounts payable and accrued expenses	10,023	11,186
Employee related accrued expenses	9,554	6,711
Other current liabilities	1,859	1,585
Total current liabilities:	21,436	19,482
Non-current liabilities:
Long-term lease liability	1,497	2,604
Uncertain tax positions liability	2,717
Total Liabilities	25,650	22,086
Commitments and contingencies (Note 17)
Shareholders' equity:
Ordinary shares, NIS 0.01 par value; 100,000,000 shares authorized at December 31, 2020 and 2019; 22,167,791 and 21,026,184 shares issued and outstanding as of December 31, 2020 and 2019, respectively	60	57
Additional paid-in capital	452,525	407,986
Accumulated deficit	(356,501)	(228,017)
Accumulated other comprehensive income	271	276
Total Shareholders' Equity	96,355	180,302
Total Liabilities and Shareholders' Equity	$ 122,005	$ 202,388

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - ₪ / shares	Dec. 31, 2020	Dec. 31, 2019
Statement Of Financial Position [Abstract]
Ordinary shares, par value	₪ 0.01	₪ 0.01
Ordinary shares, shares authorized	100,000,000	100,000,000
Ordinary shares, issued	22,167,791	21,026,184
Ordinary shares, outstanding	22,167,791	21,026,184

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Income Statement [Abstract]
Revenues, net	$ 11,799,000	$ 18,000
Cost of revenues	1,009,000
Gross profit	10,790,000	18,000
Operating expenses:
Research and development expenses	47,310,000	49,297,000
Selling, general and administrative expenses	90,219,000	60,199,000
Operating loss	(126,739,000)	(109,478,000)
Interest and other income, net	1,629,000	4,332,000
Loss before income taxes	(125,110,000)	(105,146,000)
Income tax expense	3,374,000
Net Loss	(128,484,000)	(105,146,000)
Statements of Comprehensive Loss
Net loss	(128,484,000)	(105,146,000)
Other comprehensive income
Unrealized (loss) gain on marketable securities	(5,000)	276,000
Comprehensive Loss	$ (128,489,000)	$ (104,870,000)
Loss per ordinary share basic and diluted	$ (5.90)	$ (5.12)
Weighted average number of shares outstanding used in computation of basic and diluted loss per ordinary share	21,780,826	20,528,727

CONSOLIDATED STATEMENTS OF SHAR

CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY - USD ($) $ in Thousands	Total	Ordinary Shares	Additional Paid-In Capital	Accumulated Deficit	Other Comprehensive Income
Balance at Dec. 31, 2018	$ 90,094	$ 44	$ 212,921	$ (122,871)
Balance,Share at Dec. 31, 2018		16,214,883
Exercise of options into ordinary shares	3,664	$ 2	3,662
Exercise of options into ordinary shares, shares		603,984
Share-based compensation	29,967		29,967
Issuance of ordinary shares in public offering, net of issuance expenses	161,447	$ 11	161,436
Issuance of ordinary shares in public offering, net of issuance expenses, shares		4,207,317
Other comprehensive income (loss)	276				$ 276
Net loss	(105,146)			(105,146)
Balance at Dec. 31, 2019	180,302	$ 57	407,986	(228,017)	276
Balance,Share at Dec. 31, 2019		21,026,184
Exercise of options into ordinary shares	740	$ 1	739
Exercise of options into ordinary shares, shares		441,607
Share-based compensation	28,025		28,025
Issuance of ordinary shares in public offering, net of issuance expenses	15,777	$ 2	15,775
Issuance of ordinary shares in public offering, net of issuance expenses, shares		700,000
Other comprehensive income (loss)	(5)				(5)
Net loss	(128,484)			(128,484)
Balance at Dec. 31, 2020	$ 96,355	$ 60	$ 452,525	$ (356,501)	$ 271
Balance,Share at Dec. 31, 2020		22,167,791

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Cash Flows From Operating Activities
Net loss	$ (128,484)	$ (105,146)
Adjustment to reconcile net loss to net cash from operating activities:
Depreciation and amortization	416	296
Amortization (accretion) on marketable securities	439	(572)
Stock-based compensation	28,025	29,967
Amortization of right of use asset	1,628	1,028
Lease liability	(1,541)	(910)
Changes in operating assets and liabilities:
Inventory	(1,964)
Accounts receivable	(7,047)
Prepaid expenses and other current assets	(2,330)	(394)
Accounts payable and accrued expenses	(1,245)	2,928
Employee related accrued expenses	2,843	1,786
Current tax payable	657
Uncertain tax positions	2,717
Net cash used in operating activities	(105,886)	(71,017)
Cash Flows From Investing Activities
Change in restricted deposit		(172)
Purchase of marketable securities	(29,688)	(197,686)
Maturities of marketable securities	124,141	52,590
Purchase of property and equipment	(1,215)	(325)
Net cash provided by (used in) investing activities	93,238	(145,593)
Cash Flows From Financing Activities
Proceeds from exercise of options into ordinary shares	740	3,664
Issuance of ordinary shares, net of issuance expenses	15,853	161,662
Issuance cost related to at-the-market issuances	(66)	(76)
Net cash provided by financing activities	16,527	165,250
Decrease in Cash and Cash Equivalents	3,879	(51,360)
Cash, Cash Equivalents and Restricted Cash at Beginning of Year	50,211	101,571
Cash, Cash Equivalents and Restricted Cash at End of Year	54,090	50,211
Supplemental Disclosures of Non-Cash Activities
Purchase of property and equipment	270
Issuance cost		188
New lease liabilities	$ 51	$ 1,741

Business and Nature of Operatio

Business and Nature of Operations	12 Months Ended
	Dec. 31, 2020
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Business and Nature of Operations	NOTE 1-BUSINESS AND NATURE OF OPERATIONS Nature of Operations UroGen 0 UroGen wholly owned a n UPL o l g Jelmyto On April 15, 2020, the U.S. Food and Drug Administration (“FDA”) granted expedited approval for Jelmyto Jelmyto RTGel .

Basis of Presentation

Basis of Presentation	12 Months Ended
	Dec. 31, 2020
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Basis of Presentation	NOTE 2-BASIS OF PRESENTATION The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States. The consolidated financial statements include the accounts of UPL and its wholly owned subsidiary UPI. All material intercompany balances and transactions have been eliminated during consolidation. The Company has experienced net losses since its inception and has an accumulated deficit of $356.5 million and $228.0 million as of December 31, 2020 and 2019, respectively. The Company expects to incur losses and have negative net cash flows from operating activities as it expands its portfolio and engages in further research and development activities, particularly conducting non-clinical studies and clinical trials. The success of the Company depends on the ability to successfully commercialize its technologies to support its operations and strategic plan. Based on management’s cash flow projections the Company believes that its cash and cash equivalents and marketable securities are sufficient to fund the Company’s planned operations for at least the next 12 months. The Company will need to raise additional capital to finance the continued launch of Jelmyto and support its Phase 3 ATLAS trial. There can be no assurances that the Company will be able to secure such additional financing if at all, or at terms that are satisfactory to the Company, and that it will be sufficient to meet its needs. In the event the Company is not successful in obtaining sufficient funding, this could force us to delay, limit, or reduce our product development, commercialization efforts or other operations.

Significant Accounting Policies

Significant Accounting Policies	12 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
Significant Accounting Policies	NOTE 3-SIGNIFICANT ACCOUNTING POLICIES Principles of Consolidation The Company ’ Use of Estimates The a i i n a critical estimates relate i Functional Currency The U.S. dollar (“Dollar”) is the currency of the primary economic environment in which the operations of the Company are conducted. Therefore, the functional currency of the Company is the Dollar. Accordingly, transactions in currencies other than the Dollar are measured and recorded in the functional currency using the exchange rate in effect at the date of the transaction. At the balance sheet date, monetary assets and liabilities that are denominated in currencies other than the Dollar are measured using the official exchange rate at the balance sheet date. The effects of foreign currency re-measurements are recorded in the consolidated statements of operations as “Interest and other income, net” Cash and Cash Equivalents; Marketable Securities The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. Cash and cash equivalents consist primarily of money market funds and bank money market accounts and are stated at cost, which approximates fair value. The Company classifies its marketable securities as available-for-sale in accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 320, “Investments — Debt and Equity Securities”. Available-for-sale debt securities are carried at fair value with unrealized gains and losses reported in other comprehensive income/loss within shareholders’ equity. Realized gains and losses are recorded as a component of interest and other income (expense), net. The cost of securities sold is based on the specific-identification method. Short-term investments are valued using models or other valuation methodologies that use Level 2 inputs. These models are primarily industry-standard models that consider various assumptions, including time value, yield curve, volatility factors, default rates, current market and contractual prices for the underlying financial instruments, as well as other relevant economic measures. The majority of these assumptions are observable in the marketplace, can be derived from observable data or are supported by observable levels at which transactions are executed in the marketplace. For individual debt securities classified as available-for-sale securities where there has been a decline in fair value below amortized cost, the Company determines whether the decline resulted from a credit loss or other factors. The Company records impairment relating to credit losses through an allowance for credit losses, limited by the amount that the fair value is less than the amortized cost basis. Impairment that has not been recorded through an allowance for credit losses is recorded through other comprehensive income, net of applicable taxes. Concentration of Credit Risk Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist primarily of cash and cash equivalents and marketable securities. The primary objectives for the Company ’ The Company ’ The Company’s product sales are recognized through the Company's arrangement with a single customer, a third-party national specialty distributor. The Company assesses the need for an allowance for doubtful accounts primarily based on creditworthiness, historical payment experience and general economic conditions. The Company has not experienced any credit losses related to this customer and has not currently recognized any allowance for doubtful accounts. Income Taxes The Company provides for income taxes based on pretax income, if any, and applicable tax rates available in the various jurisdictions in which it operates, including Israel and the U.S. Deferred l e n s a a The n Inventory The Company capitalizes inventory costs related to products to be sold in the ordinary course of business. The Company makes a determination of capitalizing inventory costs for a product based on, among other factors, status of regulatory approval, information regarding safety, efficacy and expectations relating to commercial sales and recoverability of costs. For Jelmyto The Company values its inventory at the lower of cost or net realizable value. The Company measures inventory approximating actual cost under a first-in, first-out basis. The Company assesses recoverability of inventory each reporting period to determine any write down to net realizable value resulting from excess or obsolete inventories. Property and Equipment Property and equipment are recorded at historical cost, net of accumulated depreciation, amortization and, if applicable, impairment charges. The Company reviews its property and equipment assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Property and equipment are depreciated over the following useful lives (in years): Useful Lives Computers and software 3 Laboratory equipment 3-6.5 Furniture 5-16.5 Manufacturing equipment 2 Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or lease terms. See Note 8 for further discussion regarding property and equipment. Leases The Company is a lessee in several noncancelable operating leases, primarily for office space, office equipment and vehicles. The Company currently has no finance leases. The Company accounts for leases in accordance with ASC Topic 842, “Leases” . Lease expense is recognized on a straight-line basis for operating leases. Variable lease payments associated with the Company’s leases are recognized when the event, activity, or circumstance in the lease agreement on which those payments are assessed occurs. Variable lease payments are presented as operating expense on the consolidated statements of operations in the same line item as expense arising from fixed lease payments. The Company’s lease terms may include options to extend the lease. The lease extensions are included in the measurement of the right of use asset and lease liability when it is reasonably certain that it will exercise that option. Because most of the Company’s leases do not provide an implicit rate of return, an incremental borrowing rate is used based on the information available at the commencement date in determining the present value of lease payments on an individual lease basis. The Company’s incremental borrowing rate for a lease is the rate of interest it would have to pay on a collateralized basis to borrow an amount equal to the lease payments under similar terms. The Company has lease agreements with lease and non-lease components. The Company applied the modified retrospective transition method and elected the transition option to use the effective date of January 1, 2019 as the date of initial application (“Transition Date”). ROU assets for operating leases are periodically reviewed for impairment losses under ASC 360-10, “Property, Plant, and Equipment”, to determine whether an ROU asset is impaired, and if so, the amount of the impairment loss to recognize. Revenues Product sales from Jelmyto Jelmyto The Company also derived revenues from its license and supply agreement with Allergan Pharmaceuticals International Limited (“Allergan”), a wholly owned subsidiary of Allergan plc which is now a part of AbbVie Inc. (the “Allergan/AbbVie Agreement”). Under the Allergan/AbbVie Agreement, the Company granted Allergan an exclusive license to develop, commercialize, and otherwise exploit products that contain reverse thermal hydrogel (“ RTGel RTGel RTGel . Research and Development Expenses Research s i d a l l Selling, General and Administrative Expenses Selling, general and administrative expenses consist primarily of personnel costs (including share-based compensation related to directors, employees and consultants). Other significant costs include commercial, medical affairs, external professional service costs, facility costs, accounting and audit services, legal services and other consulting fees. Selling, general and administrative costs are expensed as incurred. The Company accrues for services provided by third parties related to the above expenses by monitoring the status of services provided and receiving estimates from its service providers and adjusting its accruals as actual costs become known. Share-Based Compensation Share-based compensation cost is measured at the grant date based on the fair value of the award and is recognized as expense over the required service period, which is equal to the vesting period. The fair value of options is determined using the Black-Scholes option-pricing model. The fair value of a restricted stock unit (“RSU”) equaled the closing price of the Company’s ordinary shares on the grant date. The The s n g Net Loss per Ordinary Share Basic net loss per share is computed by dividing the net loss attributable to ordinary shareholders by the weighted-average number of ordinary shares outstanding. Diluted net loss per share is computed similarly to basic net loss per share except that the denominator is increased to include the number of additional ordinary shares that would have been outstanding if the potential ordinary shares had been issued and if the additional ordinary shares were dilutive. For all periods presented, potentially dilutive securities are excluded from the computation of fully diluted loss per share as their effect is anti-dilutive. The following table summarizes the calculation of basic and diluted loss per common share for the periods presented (in thousands, except share and per share amounts): Year Ended December 31, 2020 2019 Basic and diluted: Loss attributable to equity holders of the Company $ 128,484 $ 105,146 Loss attributable to equity holders of the Company, after deducting dividend accumulated for preferred shares $ 128,484 $ 105,146 Weighted-average number of ordinary shares 21,780,826 20,528,727 Loss per ordinary share $ 5.90 $ 5.12 Recently Adopted Accounting Pronouncements In June 2016, the Financial Accounting Standards Board, or FASB, issued Accounting Standards Update, or ASU, No. 2016-13, Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments, or ASU 2016-13. ASU 2016-13 requires the Company to measure and recognize expected credit losses for certain financial instruments, including trade receivables, as an allowance that reflects the Company’s current estimate of credit losses expected to be incurred. For available-for-sale debt securities with unrealized losses, the standard requires allowances to be recorded through net income instead of directly reducing the amortized cost of the investment under the prior other-than-temporary impairment model. The Company applied the modified retrospective transition method as of the date of initial application, January 1, 2020. As of December 31, 2020, the Company believes the cost basis for its marketable securities were recoverable in all material aspects and no credit impairments were recognized in the period. Similarly, the Company estimates minimal current expected credit losses on trade receivables and has not recognized any allowance for doubtful accounts in the period.

Other Financial Information

Other Financial Information	12 Months Ended
	Dec. 31, 2020
Other Financial Information [Abstract]
Other Financial Information	NOTE 4-OTHER FINANCIAL INFORMATION Accounts Payable and Accrued Expenses Accounts payable and accrued expenses consist of the following as of December 31, 2020 and 2019 (in thousands): December 31, 2020 December 31, 2019 Accounts payable $ 3,271 $ 4,694 Accrued sales reserves 382 — Accrued clinical expenses 1,359 399 Accrued research and development costs 1,356 2,644 Accrued general and administrative expenses 2,440 2,767 Accrued other expense 1,215 682 Total accrued expenses and other current liabilities $ 10,023 $ 11,186 Interest and Other Income (Expenses), Net Interest and other income (expenses) consisted of the following as of December 31, 2020 and 2019 (in thousands): Year Ended December 31, 2020 2019 Interest income 1,986 4,616 Other finance expenses (357 ) (284 ) Total interest and other income $ 1,629 $ 4,332

Inventories

Inventories	12 Months Ended
	Dec. 31, 2020
Inventory Disclosure [Abstract]
Inventories	NOTE 5-INVENTORIES Inventories consist of the following as of December 31, 2020 and December 31, 2019 (in thousands): December 31, 2020 December 31, 2019 Raw materials $ 1,051 — Finished goods 913 — Total inventories $ 1,964 $ —

Fair Value Measurements

Fair Value Measurements	12 Months Ended
	Dec. 31, 2020
Fair Value Disclosures [Abstract]
Fair Value Measurements	NOTE 6-FAIR VALUE MEASUREMENTS The Company follows authoritative accounting guidance, which among other things, defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, a three-tier fair value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows: Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. Level 3: Unobservable inputs that reflect the reporting entity ’ s own assumptions. The carrying amounts of the Company ’ Assets and liabilities measured at fair value on a recurring basis based on Level 1 and Level 2 fair value measurement criteria as of December 31, 2020 are as follows (in thousands): Fair Value Measurements Using Quoted Prices Significant in Active Other Balance as of Markets for Observable December 31, Identical Assets Inputs 2020 (Level 1) (Level 2) Marketable securities: US government $ 29,186 $ 29,186 $ — Corporate bonds 21,861 — 21,861 Money market funds (1) 39,744 39,744 — Total marketable securities $ 90,791 $ 68,930 $ 21,861 (1) Included within cash and cash equivalents on the Company s consolidated balance sheets. Assets and liabilities measured at fair value on a recurring basis based on Level 1 and Level 2 fair value measurement criteria as of December 31, 2019 are as follows (in thousands): Fair Value Measurements Using Quoted Prices Significant in Active Other Balance as of Markets for Observable December 31, Identical Assets Inputs 2019 (Level 1) (Level 2) Marketable securities: US government $ 66,094 $ 66,094 $ — Corporate bonds 68,084 — 68,084 Commercial paper 7,658 — 7,658 Money market funds (1) 16,998 16,998 — Certificates of deposit 4,108 — 4,108 Total marketable securities $ 162,942 $ 83,092 $ 79,850 (1) Included within cash and cash equivalents on the Company s consolidated balance sheets. The Company ’

Marketable Securities

Marketable Securities	12 Months Ended
	Dec. 31, 2020
Investments Debt And Equity Securities [Abstract]
Marketable Securities	NOTE 7-MARKETABLE SECURITIES The following table summarizes the Company’s marketable securities as of December 31, 2020 (in thousands): Amortized Cost Basis Unrealized Gains Fair Value Marketable securities: US government $ 28,970 $ 216 $ 29,186 Corporate bonds 21,806 55 21,861 Money market funds (1) 39,744 — 39,744 Total marketable securities $ 90,520 $ 271 $ 90,791 (1) Included within cash and cash equivalents on the Company s consolidated balance sheets. The Company classifies its marketable securities as available-for-sale, and they consist of all debt securities. As of December 31, 2020, they were in a net unrealized gain position of $0.3 million. Unrealized gains and losses on available-for-sale debt securities are included as a component of comprehensive loss. As of December 31, 2020, the Company did not hold any marketable securities in an unrealized loss position. In accordance with the Company’s general investment strategy, the Company does not intend to sell the investments before maturity. As of December 31, 2020, the Company believes the cost basis for its marketable securities were recoverable in all material aspects and no credit impairments were recognized in the period. The Company’s marketable securities as of December 31, 2020 mature at various dates through February 2022. The fair values of marketable securities by contractual maturity consist of the following (in thousands): December 31, 2020 December 31, 2019 Maturities within one year $ 88,898 $ 114,386 Maturities after one year through three years 1,893 48,556 Total marketable securities $ 90,791 $ 162,942

Property and Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2020
Property Plant And Equipment [Abstract]
Property and Equipment	NOTE 8-PROPERTY AND EQUIPMENT Property and equipment, consists of the following as of December 31, 2020 and 2019 (in thousands): December 31, 2020 2019 Laboratory equipment $ 333 $ 259 Computer equipment and software 1,676 416 Furniture 597 544 Leasehold improvements 609 530 Manufacturing equipment 226 226 3,441 1,975 Less: accumulated depreciation and amortization (1,395 ) (998 ) Property and equipment, net $ 2,046 $ 977 Depreciation and amortization expense was $0.4 million and $0.3 million for the years ended December 31, 2020 and 2019, respectively.

Leases

Leases	12 Months Ended
	Dec. 31, 2020
Leases [Abstract]
Leases	NOTE 9-LEASES Operating Leases The Company has the following office and laboratory facility leases: • In April 2016, UPL signed an addendum to its November 2014 lease agreement for the Company’s executive offices located in Israel, in order to increase the office space rented and to extend the rent period until 2019. In March 2019, UPL exercised the agreement extension option and extended the rental period for an additional three years until August 2022. • In September 2017, UPI entered into a new lease agreement for its office space in New York, which the Company previously used as its headquarters. The lease agreement commenced in October 2017 and terminates in February 2021. In October 2020, the Company committed to and announced a plan to close the New York office and fully impaired the associated right of use asset. • In April 2018, UPI entered into a new lease agreement for an office in Los Angeles, California. The lease commencement date was July 10, 2018 and terminates in March 2024. The landlord provided a tenant allowance for leasehold improvements of $0.2 million that was accounted for as a lease incentive. The Company’s remaining contractual obligation under this lease is approximately $0.9 million as of December 31, 2020. In November 2019, UPI entered into a sublease for this office space, with a lease commencement date of January 1, 2020 and continuing until the end of the lease term in March 2024. The subtenants exercised their early access clause and moved into the premises the end of November 2019. The remaining rental payments to be received over the lease term is approximately $0.7 million as of December 31, 2020 . The Company accounts for the sublease as on operating lease in accordance with ASC 842-10-25-2 and ASC 842-10-25-3. The main lease was considered for impairment and the amount was determined to be immaterial. • In November 2019, UPI entered into a new lease agreement for an office in Princeton, New Jersey, which the Company now uses as its headquarters. The lease commencement date was November 29, 2019 and the lease term is 38 months. The Company’s remaining contractual obligation under this lease is approximately $1.2 million as of December 31, 2020. In addition, the Company leases operating office equipment and vehicles. The Company’s operating leases may require minimum rent payments, contingent rent payments adjusted periodically for inflation, or rent payments equal to the greater of a minimum rent or contingent rent. The Company’s leases do not contain any residual value guarantees or material restrictive covenants. The Company’s leases expire at various dates from 2021 through 2023, with varying renewal and termination options. The components of lease cost for the year ended December 31, 2020 were as follows (in thousands) Year Ended December 31, 2020 Operating lease cost $ 1,812 Sublease income (224 ) Variable lease cost 129 $ 1,717 The amounts recognized as of December 31, 2020 were as follows (in thousands): December 31, 2020 Right of use asset $ 2,158 Long-term lease liability 1,497 Other current liabilities 1,202 In October 2020, the Company committed to and announced a plan to close the New York office and recognized impairment losses of approximately $0.2 million in relation to the associated right of use asset. Supplemental information related to leases for the periods reported is as follows (in thousands): Year Ended December 31, 2020 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases 1,726 Right-of-use assets obtained in exchange for new operating lease liabilities 135 Weighted-average remaining lease term of operating leases 2.26 years Weighted-average discount rate of operating leases 5.38% As of December 31, 2020, maturities of lease liabilities were as follows (in thousands): Operating Leases Years ending December 31, 2021 $ 1,307 2022 1,150 2023 357 2024 58 2025 and thereafter — Total future minimum lease payments $ 2,872 Less: Interest (173 ) Present value of lease liabilities $ 2,699 As of December 31, 2019, maturities of lease liabilities were as follows (in thousands): Operating Leases Years ending December 31, 2020 $ 1,758 2021 1,269 2022 1,101 2023 348 2024 and thereafter 58 Total future minimum lease payments $ 4,534 Subleases As of December 31, 2020, undiscounted cash flows to be received under the Company’s operating sublease on an annual basis was as follows (in thousands): Operating Leases Years ending December 31, 2021 $ 235 2022 243 2023 251 2024 49 2025 and thereafter — Total future minimum sublease payments $ 778 Sublease income is recognized net within operating expenses. Sublease income for the year ended December 31, 2020 was as follows (in thousands): Year Ended December 31, 2020 Sublease income from fixed lease payments $ 224

Revenue from Product Sales

Revenue from Product Sales	12 Months Ended
	Dec. 31, 2020
Revenue From Contract With Customer [Abstract]
Revenue from Product Sales	NOTE 10-REVENUE FROM PRODUCT SALES Net product sales consist of the following for the year ended December 31, 2020 and 2019 (in thousands): Year Ended December 31, 2020 December 31, 2019 Jelmyto $ 11,799 $ —

License and Collaboration Agree

License and Collaboration Agreements	12 Months Ended
	Dec. 31, 2020
Liscense Agreement [Abstract]
License and Collaboration Agreements	NOTE 11- LICENSE AND COLLABORATION AGREEMENTS Allergan/AbbVie Agreement In October 2016, the Company entered into the Allergan/AbbVie Agreement and granted Allergan (now part of AbbVie) an exclusive worldwide license to research, develop, manufacture and commercialize pharmaceutical products that contain RTGel ® Under the Allergan/AbbVie Agreement, Allergan is solely responsible for costs and development of the Licensed Products and obtaining all regulatory approvals for Licensed Products worldwide, as well as worldwide commercialization of the Licensed Products after receiving the regulatory approval to do so. Allergan is required to use commercially reasonable efforts to develop and commercialize the Licensed Products for overactive bladder in certain major market countries. Further, the Company is eligible to receive additional material milestone payments of up to an aggregate of $200.0 million upon the successful completion of certain development, regulatory and commercial milestones. As of December 31, 2020, since inception of the Allergan/AbbVie Agreement the Company has received a total of $25.0 million in milestone payments from Allergan. Allergan will pay the Company a tiered royalty in the low single digits based on worldwide annual net sales of Licensed Products, subject to certain reductions for the market entry of competing products and/or loss of the Company’s patent coverage of Licensed Products. The Company is responsible for payments to any third party for certain RTGel Under the Allergan/AbbVie Agreement, Allergan granted the Company a non-exclusive, sublicensable, fully paid-up, perpetual, worldwide license under any improvements Allergan makes to the composition, formulation, or manufacture of RTGel RTGel In August 2020, the Company announced that the Phase 2 APOLLO trial did not meet the primary endpoint, it is believed to be the result of BOTOX not effectively permeating the urothelium. The Company and AbbVie are continuing to explore the potential use of RTGel Agenus Agreement In November 2019, the Company entered into a license agreement with Agenus Inc, pursuant to which Agenus granted to the Company an exclusive, worldwide (not including Argentina, Brazil, Chile, Colombia, Peru, Venezuela and their respective territories and possessions), royalty-bearing, sublicensable license under Agenus’s intellectual property rights to develop, make, use, sell, import, and otherwise commercialize products incorporating a proprietary antibody of Agenus known as AGEN1884 for the treatment of cancers of the urinary tract via intravesical delivery. AGEN1884 is an anti-CTLA-4 antagonist that is currently being evaluated by Agenus as a monotherapy in PD-1 refractory patients and in combination with Agenus’ anti-PD-1 antibody in solid tumors. Initially, the Company plans to develop AGEN1884 in combination with UGN-201 for the treatment of high-grade NMIBC cancer. Pursuant to the license Agreement, the Company paid Agenus an upfront fee of $10.0 million and has agreed to pay Agenus up to $115.0 million upon achieving certain clinical development and regulatory milestones, up to $85.0 million upon achieving certain commercial milestones, and royalties on net sales of licensed products in the 14%-20% range. The Company will be responsible for all development and commercialization activities. Under the terms of the license agreement, Agenus has agreed to use commercially reasonable efforts to supply AGEN1884 to the Company for use in preclinical studies or clinical trials. Unless earlier terminated in accordance with the terms of the license agreement, the license agreement will expire on a product-by-product and country-by-country basis at the later of (a) the expiration of the last to expire valid claim of a licensed patent right that covers the licensed product in such country or (b) 15 years after the first commercial sale of the licensed product in such country. The Company may terminate the license agreement for convenience upon 180 days’ written notice to Agenus. Either party may terminate the license agreement upon 60 days’ notice to the other party if, prior to the first commercial sale of a licensed product, the Company substantially ceases to conduct development activities of the licensed products for nine consecutive months (and during such period, Agenus has complied with its obligations under the license agreement) other than in response to a requirement of an applicable regulatory authority or an event outside of the Company’s control. In addition, either party may terminate the license agreement in the event of an uncured material breach of the other party. The Company recorded the $10.0 million milestone in acquired in-process research and development expenses for the year ended December 31, 2019.

Employee Rights Upon Retirement

Employee Rights Upon Retirement	12 Months Ended
	Dec. 31, 2020
Employee Rights Upon Retirement [Abstract]
Employee Rights Upon Retirement	NOTE In Israel, the e The a g n i o c The n j i p

Shareholders' Equity

Shareholders' Equity	12 Months Ended
	Dec. 31, 2020
Equity [Abstract]
Shareholders' Equity	NOTE 13-SHAREHOLDERS’ EQUITY Ordinary Shares The Company had 100.0 million ordinary shares authorized for issuance as of December d w a In January 2019, the Company completed an underwritten public offering of 4,207,317 of its ordinary shares, including 548,780 shares sold pursuant to the full exercise of the underwriters’ option to purchase additional shares, at a price to the public of $41.00 per share. The net proceeds to the Company from the offering were approximately $161.4 million, after deducting the underwriting discounts and commissions and payment of other offering expenses. In December 2019, the Company entered into a sales agreement (the “ATM Sales Agreement”) w ith Cowen and Company, LLC (“Cowen”), to or through Cowen, acting as sales agent or principal

Share-Based Compensation

Share-Based Compensation	12 Months Ended
	Dec. 31, 2020
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Share-Based Compensation	NOTE 14-SHARE-BASED COMPENSATION In a The b the “capital gains” track, as set out in Section 102. The Company registered the Plan un d er the capital gains track, which offers more favorable tax rates to the employees. As a result, and pursuant to the terms of Section 102, the Company is not allowed to claim as an ex p ense for tax purposes the amounts credited to the employees in respect of options granted to them under the P l an, including amounts recorded as salary be n efits in the Company’s accounts, with the exception of the work-income b e nefit component, if any, determined on grant date. For non-employees and for non-Israeli employees, the Plan is subject to Section 3(i) of the Israeli Income Tax Ordinance. Employees are typically granted stock options and/or restricted stock units, or RSUs, upon commencement of employment. Also, eligible employees may receive an annual grant of options or RSU’s. Non-employee members of the Board typically receive a grant of RSUs and/or stock options annually. The term of any option granted under the Plan cannot exceed 10 years. Options shall not have an exercise price less than 100% of the fair market value of the Company’s ordinary shares on the grant date, and generally vest over a period of three years. If the individual possesses more than 10% of the combined voting power of all classes of equity of the Company, the exercise price shall not be less than 110% of the fair market value of an ordinary share of stock on the date of grant. The Company’s RSU and option grants provide for accelerated or continued vesting in certain circumstances as defined in the plans and related grant agreements, including a termination in connection with a change in control. RSUs generally vest in a 33% increment upon the first anniversary of grant, and in either equal quarterly or annual amounts for the two years following the one-year anniversary of the grant date. Options generally vest in a 33% increment upon the first anniversary of the grant date, and in either equal quarterly or annual amounts for the two years following the one-year anniversary of the grant date. In March 2017, the Board adopted the 2017 Equity Incentive Plan (the "2017 Plan"), which was approved by the shareholders in April 2017. The 2017 Plan provides for the grant of incentive stock options to the Company's employees and for the grant of nonstatutory stock options, stock appreciation rights, restricted stock awards, RSU awards, performance share awards, performance cash awards, and other forms of share awards to the Company's employees, directors and consultants. The maximum number of ordinary shares that may initially be issued under the 2017 Plan is 1,400,000. In addition, the number of ordinary shares reserved for issuance under the 2017 Plan will automatically increase on January 1st of each calendar year, from January 1, 2018 through January 1, 2026, so that the number of such shares reserved for issuance will equal 12% of the total number of ordinary shares outstanding on the last day of the calendar month prior to the date of each automatic increase, or a lesser number of shares determined by the Board. The maximum number of ordinary shares that may be issued upon the exercise of stock options under the 2017 Plan is 5,600,000. On January 1, 2018, the share reserve increased by 250,167 to 1,650,167. On October 12, 2018, the Company increased the amount of registered ordinary shares of the Company’s 2017 Plan by 1,900,000 to 3,550,167. On June 8, 2020 the Company increased the amount of registered ordinary of the Company’s 2017 plan by 400,000 to 3,950,167. On January 3, 2019, the Company appointed Elizabeth Barrett as its President and Chief Executive Officer. In connection with Ms. Barrett’s employment, she was granted 277,432 options to purchase the Company’s ordinary shares, at an exercise price of $47.57, as well as 317,065 RSUs, with a combined grant-date fair value of $24.1 million. In May 2019, the Company adopted the UroGen Pharma Ltd. 2019 Inducement Plan (the “Inducement Plan”). Under the Inducement Plan, the Company is authorized to issue up to 900,000 ordinary shares pursuant to awards issued under the Inducement Plan. The only persons eligible to receive grants of Awards (as defined below) under the Inducement Plan are individuals who satisfy the standards for inducement grants under Nasdaq Marketplace Rule 5635(c)(4) or 5635(c)(3) and the related guidance under Nasdaq IM 5635-1, including individuals who were not previously an employee or director of the Company or are following a bona fide period of non-employment, in each case as an inducement material to such individual’s agreement to enter into employment with the Company. Under the Inducement Plan, an “Award” is a nonstatutory stock option, restricted stock unit or other right to receive ordinary shares pursuant to the Inducement Plan. In June 2019, the Board approved grants of 70,000 options to its non-employee directors. Each then current non-employee director, including the Chairman of the Board, received a grant of 10,000 options. Each option is exercisable into one ordinary share of the Company’s stock at an exercise price of $34.83 per share. The options vest quarterly over one year and expire 10 years from grant date. The grant date fair value of these options was approximately $1.9 million. In December 2019, the Board approved a modification of options and RSU's for a consultant. The Company recorded an expense of $0.9 million under general and administrative expenses with respect to options' modification. No In June 2020, the Board approved grants of an aggregate of 70,000 options to its non-employee directors. Each non-employee director, including the Chairman of the Board, received a grant of 10,000 options. Each option is exercisable into one ordinary share of the Company’s stock at an exercise price of $28.24 per share. The options vest quarterly over one year and expire 10 years from the grant date. The grant date fair value of these options was approximately $1.5 million. Options : Set a) During 2020, the Company granted 400,600 options with exercise prices ranging from $16.50 to $29.41 per share. b) During n The fair value of options granted during 2020 and 2019 was $6.7 and $27.6 million, respectively. The o c The e 2020 2019 Value of ordinary shares $16.50-29.41 $33.21-47.57 Dividend yield 0% 0% Expected volatility 71.43%-79.80% 74.09%-80.52% Risk-free interest rate 0.37%-1.35% 1.36%-2.62% Expected term 5.9-10 years 5.8-10 years The on a mix of the Company's historical volatility and c e The employee and non-employee o b a Number of options Weighted Average price per share Outstanding as of January 1, 2019 2,522,981 $ 26.16 Granted 955,732 41.96 Canceled/Forfeited (183,725 ) 41.85 Exercised (423,653 ) 9.10 Outstanding as of December 31, 2019 2,871,335 $ 32.93 Granted 400,600 24.33 Canceled/Forfeited (408,534 ) 44.68 Exercised (137,070 ) 5.40 Outstanding as of December 31, 2020 2,726,331 $ 31.29 The intrinsic value of stock options exercised was $2.3 million and $14.2 million for the years ended December 31, 2020 and 2019, respectively. The i Options outstanding Options exercisable Exercise price per share Number of options outstanding at end of year Weighted average remaining contractual life Number of options exercisable at end of year Weighted average remaining contractual life $0.00 - 10.00 588,324 1.99 588,324 1.99 $10.01 - 20.00 268,000 8.77 75,000 6.39 $20.01 - 30.00 272,800 8.19 139,999 7.24 $30.01 - 40.00 413,500 6.72 340,833 6.36 $40.01 - 50.00 1,063,041 7.17 771,250 6.93 $50.01 - 59.23 120,666 7.00 115,332 6.98 2,726,331 2,030,738 The x The following table summarizes information about RSU activity as of December 31, 2020: Outstanding Restricted Stock Units Outstanding as of January 1, 2019 263,699 Granted 455,465 Vested and released (183,975 ) Forfeited (15,762 ) Outstanding as of December 31, 2019 519,427 Granted 591,480 Vested and released (304,537 ) Forfeited (85,954 ) Outstanding as of December 31, 2020 720,416 The fair value of RSUs granted during 2020 and 2019 was $15.6 and $19.9 million, respectively. The total unrecognized compensation cost of RSUs as of December 31, 2020 is $17.6 million with a weighted average recognition period of 1.84 years. The p Year ended December 31, 2020 2019 Research and development expenses $ 6,432 $ 8,291 Selling, general and administrative expenses 21,593 21,676 Total share-based compensation expense $ 28,025 $ 29,967

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Income Taxes	NOTE 15-INCOME TAXES The Corporate tax rate The applicable Israeli tax rate relevant to the Company for 2018 and thereafter is 23%. For financial reporting purposes, the expense for current income taxes consists of the following: 2020 2019 Current taxes: U.S. Federal $ 3,218 - U.S. State 156 - Total current taxes $ 3,374 - Deferred Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company and its subsidiary deferred tax assets are as follows: December 31, 2020 2019 In respect of: Net operating loss carryforward $ 57,607 $ 33,817 Research and development expenses 5,362 4,591 Stock-based compensation 9,278 6,543 Issuance costs 978 2,063 In-process research and development 2,329 2,749 Right of use asset (372 ) (800 ) Lease Liability 473 896 Accrued expenses 1,589 762 Depreciation of fixed assets (299 ) (90 ) Other 18 62 Less—valuation allowance (76,963 ) (50,593 ) Net deferred tax assets $ — $ — The change in valuation allowance for the years ended December 31, 2020 and 2019 were as follows: 2020 2019 Balance at the beginning of the year $ (50,593 ) $ (28,249 ) Changes during the year (26,370 ) (22,344 ) Balance at the end of the year $ (76,963 ) $ (50,593 ) The main reconciling item between the statutory tax rates of the Company and the effective rate is the share-based compensation , the provision for a full valuation allowance in respect of tax benefits from carryforward tax losses due to the uncertainty of the realization of such tax benefits , and expense related to uncertain tax positions . A reconciliation of the Company’s statutory tax rate to effective tax is as follows: December 31, 2020 2019 Pretax income $ (125,110 ) $ (105,146 ) Statutory rate 23% 23% Income tax expense/(benefit) at statutory rate (28,775 ) (24,184 ) Additional tax (tax saving) in respect of: Non-deductible expenses 1,439 2,076 Different tax rate of foreign subsidiaries 17 20 Uncertain tax positions 2,717 - Change in valuation allowance 26,370 22,344 Other 1,607 (257 ) Income tax expense $ 3,374 $ - The Internal Revenue Code contains provisions that may limit our use of federal net operating loss carryforwards if significant changes occur in the constructive stock ownership of UroGen Pharma Inc Losses for tax purposes carried forward to future years As of December 31, 2020, and December 31, 2019, the Company had approximately $250.2 and $151.9 million of net carryforward tax losses, respectively, available to reduce future taxable income without limitation of use. Uncertain tax positions A reconciliation of the beginning and ending amount of uncertain tax positions is as follows: 2020 2019 Uncertain tax positions at the beginning of the year - - Gross increases — tax positions in current period 2,717 - Gross increases — tax positions in prior period - - Uncertain tax positions at the end of the year 2,717 - The balances of uncertain tax positions as of December 31, 2020 would affect the Company’s effective tax rate if recognized. The Company has recorded liabilities for uncertain tax positions of $2.7 million as of December 31, 2020 for tax positions relating to transfer pricing between affiliated entities. The Company recognizes interest accrued and penalties related to uncertain tax positions as a component of income tax expense. As of December 31, 2020, the Company has accrued $0.7 million of interest and penalties related to uncertain tax positions. The Company operates on a global basis and is subject to tax laws and regulations in the US and Israel. The estimate of the Company’s tax liabilities relating to uncertain tax positions requires management to assess uncertainties and to make judgments about the application of complex tax laws and regulations, expectations regarding the outcome of tax authority examinations, as well as the ultimate measurement of potential liabilities. The uncertain tax positions are reviewed quarterly and adjusted as events occur that could affect potential liabilities for additional taxes, including lapsing of applicable statutes of limitations, correspondence with tax authorities, proposed assessments by tax authorities, identification of new issues, and issuance of new legislation or regulations. The Company believes that adequate amounts of tax have been provided in income tax expense for any adjustments that may result from its uncertain tax positions. Based upon the information currently available, the Company does not reasonably expect changes in its existing uncertain tax positions in the next 12 months and have recorded the gross uncertain tax positions as a long-term liability. The Company has received final tax assessments up to and including its 2014 tax year.

Related Parties

Related Parties	12 Months Ended
	Dec. 31, 2020
Related Party Transactions [Abstract]
Related Parties	NOTE 16-RELATED PARTIES There were no related party transactions for the year ended December 31, 2020 or 2019.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2020
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	NOTE 17-COMMITMENTS AND CONTINGENCIES In the normal course of business, the Company enters into contracts that contain a variety of indemnifications with its employees, licensors, suppliers and service providers. Further, the Company indemnifies its directors and officers who are, or were, serving at the Company ’ ’ Grants (“ The n d Israeli Ministry of Industry and Commerce On January 12, 2020, the IIA Office of Chief Scientist approved the Company's request to unwind its obligation to the IIA regarding grants that were loaned to the Company between January 2004 and September 2016. The total payment under the IIA approval, net of the royalties already paid, $6.6 million, was fully paid during the first quarter of 2020 and recognized as research and development expense. Based on this payment, the Company will have full freedom to transfer IIA-funded technology or manufacture products developed with IIA-funded technology outside of the State of Israel. Other than the commitment to continue at least 75% of its based R&D jobs in Israel (at the time of settlement) for a period of at least three years, all other obligations with the IIA ceased to exist as per the agreement. Separation Agreement On September 7, 2020, the Company entered into a Separation Agreement with Peter Pfreundschuh, the Company’s Chief Financial Officer, which sets forth the terms of Mr. Pfreundschuh’s termination of employment with the Company, effective as of October 15, 2020. The arrangement includes cash severance, a pro rata portion of the target annual bonus for calendar year 2020 contingent on certain performance conditions, and partial acceleration of share-based compensation. The Company recognized $0.7 million during the year ended December 31, 2020 in relation to this arrangement.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2020
Subsequent Events [Abstract]
Subsequent Events	NOTE 18-SUBSEQUENT EVENTS In January 2021, the Company announced that it entered into a three-year strategic research collaboration agreement with MD Anderson focusing on UGN-302 as an investigational treatment for high-grade NMIBC. Under the agreement, MD Anderson and the Company will collaborate on the design and conduct of non-clinical and clinical studies with oversight from a joint steering committee. The Company will provide funding, developmental candidates, and other support. Pursuant to the agreement, the Company made an upfront payment to MD Anderson of $500,000. In March 2021, the Company announced a transaction with RTW Investments (“RTW”) totaling $75.0 million in funding for the Company to support the launch of Jelmyto and the development of UGN-102. RTW will provide the Company with an upfront cash payment of $75.0 million and will receive tiered future payments based on global annual net product sales of Jelmyto and UGN-102, if approved.

Significant Accounting Polici_2

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation The Company ’
Use of Estimates	Use of Estimates The a i i n a critical estimates relate i
Functional Currency	Functional Currency The U.S. dollar (“Dollar”) is the currency of the primary economic environment in which the operations of the Company are conducted. Therefore, the functional currency of the Company is the Dollar. Accordingly, transactions in currencies other than the Dollar are measured and recorded in the functional currency using the exchange rate in effect at the date of the transaction. At the balance sheet date, monetary assets and liabilities that are denominated in currencies other than the Dollar are measured using the official exchange rate at the balance sheet date. The effects of foreign currency re-measurements are recorded in the consolidated statements of operations as “Interest and other income, net”
Cash and Cash Equivalents; Marketable Securities	Cash and Cash Equivalents; Marketable Securities The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. Cash and cash equivalents consist primarily of money market funds and bank money market accounts and are stated at cost, which approximates fair value. The Company classifies its marketable securities as available-for-sale in accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 320, “Investments — Debt and Equity Securities”. Available-for-sale debt securities are carried at fair value with unrealized gains and losses reported in other comprehensive income/loss within shareholders’ equity. Realized gains and losses are recorded as a component of interest and other income (expense), net. The cost of securities sold is based on the specific-identification method. Short-term investments are valued using models or other valuation methodologies that use Level 2 inputs. These models are primarily industry-standard models that consider various assumptions, including time value, yield curve, volatility factors, default rates, current market and contractual prices for the underlying financial instruments, as well as other relevant economic measures. The majority of these assumptions are observable in the marketplace, can be derived from observable data or are supported by observable levels at which transactions are executed in the marketplace. For individual debt securities classified as available-for-sale securities where there has been a decline in fair value below amortized cost, the Company determines whether the decline resulted from a credit loss or other factors. The Company records impairment relating to credit losses through an allowance for credit losses, limited by the amount that the fair value is less than the amortized cost basis. Impairment that has not been recorded through an allowance for credit losses is recorded through other comprehensive income, net of applicable taxes.
Concentration of Credit Risk	Concentration of Credit Risk Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist primarily of cash and cash equivalents and marketable securities. The primary objectives for the Company ’ The Company ’ The Company’s product sales are recognized through the Company's arrangement with a single customer, a third-party national specialty distributor. The Company assesses the need for an allowance for doubtful accounts primarily based on creditworthiness, historical payment experience and general economic conditions. The Company has not experienced any credit losses related to this customer and has not currently recognized any allowance for doubtful accounts.
Income Taxes	Income Taxes The Company provides for income taxes based on pretax income, if any, and applicable tax rates available in the various jurisdictions in which it operates, including Israel and the U.S. Deferred l e n s a a The n
Inventory	Inventory The Company capitalizes inventory costs related to products to be sold in the ordinary course of business. The Company makes a determination of capitalizing inventory costs for a product based on, among other factors, status of regulatory approval, information regarding safety, efficacy and expectations relating to commercial sales and recoverability of costs. For Jelmyto The Company values its inventory at the lower of cost or net realizable value. The Company measures inventory approximating actual cost under a first-in, first-out basis. The Company assesses recoverability of inventory each reporting period to determine any write down to net realizable value resulting from excess or obsolete inventories.
Property and Equipment	Property and Equipment Property and equipment are recorded at historical cost, net of accumulated depreciation, amortization and, if applicable, impairment charges. The Company reviews its property and equipment assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Property and equipment are depreciated over the following useful lives (in years): Useful Lives Computers and software 3 Laboratory equipment 3-6.5 Furniture 5-16.5 Manufacturing equipment 2 Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or lease terms. See Note 8 for further discussion regarding property and equipment.
Leases	Leases The Company is a lessee in several noncancelable operating leases, primarily for office space, office equipment and vehicles. The Company currently has no finance leases. The Company accounts for leases in accordance with ASC Topic 842, “Leases” . Lease expense is recognized on a straight-line basis for operating leases. Variable lease payments associated with the Company’s leases are recognized when the event, activity, or circumstance in the lease agreement on which those payments are assessed occurs. Variable lease payments are presented as operating expense on the consolidated statements of operations in the same line item as expense arising from fixed lease payments. The Company’s lease terms may include options to extend the lease. The lease extensions are included in the measurement of the right of use asset and lease liability when it is reasonably certain that it will exercise that option. Because most of the Company’s leases do not provide an implicit rate of return, an incremental borrowing rate is used based on the information available at the commencement date in determining the present value of lease payments on an individual lease basis. The Company’s incremental borrowing rate for a lease is the rate of interest it would have to pay on a collateralized basis to borrow an amount equal to the lease payments under similar terms. The Company has lease agreements with lease and non-lease components. The Company applied the modified retrospective transition method and elected the transition option to use the effective date of January 1, 2019 as the date of initial application (“Transition Date”). ROU assets for operating leases are periodically reviewed for impairment losses under ASC 360-10, “Property, Plant, and Equipment”, to determine whether an ROU asset is impaired, and if so, the amount of the impairment loss to recognize.
Revenues	Revenues Product sales from Jelmyto Jelmyto The Company also derived revenues from its license and supply agreement with Allergan Pharmaceuticals International Limited (“Allergan”), a wholly owned subsidiary of Allergan plc which is now a part of AbbVie Inc. (the “Allergan/AbbVie Agreement”). Under the Allergan/AbbVie Agreement, the Company granted Allergan an exclusive license to develop, commercialize, and otherwise exploit products that contain reverse thermal hydrogel (“ RTGel RTGel RTGel .
Research and Development Expenses	Research and Development Expenses Research s i d a l l
Selling General and Administrative Expenses	Selling, General and Administrative Expenses Selling, general and administrative expenses consist primarily of personnel costs (including share-based compensation related to directors, employees and consultants). Other significant costs include commercial, medical affairs, external professional service costs, facility costs, accounting and audit services, legal services and other consulting fees. Selling, general and administrative costs are expensed as incurred. The Company accrues for services provided by third parties related to the above expenses by monitoring the status of services provided and receiving estimates from its service providers and adjusting its accruals as actual costs become known.
Share-Based Compensation	Share-Based Compensation Share-based compensation cost is measured at the grant date based on the fair value of the award and is recognized as expense over the required service period, which is equal to the vesting period. The fair value of options is determined using the Black-Scholes option-pricing model. The fair value of a restricted stock unit (“RSU”) equaled the closing price of the Company’s ordinary shares on the grant date. The The s n g
Net Loss per Ordinary Share	Net Loss per Ordinary Share Basic net loss per share is computed by dividing the net loss attributable to ordinary shareholders by the weighted-average number of ordinary shares outstanding. Diluted net loss per share is computed similarly to basic net loss per share except that the denominator is increased to include the number of additional ordinary shares that would have been outstanding if the potential ordinary shares had been issued and if the additional ordinary shares were dilutive. For all periods presented, potentially dilutive securities are excluded from the computation of fully diluted loss per share as their effect is anti-dilutive. The following table summarizes the calculation of basic and diluted loss per common share for the periods presented (in thousands, except share and per share amounts): Year Ended December 31, 2020 2019 Basic and diluted: Loss attributable to equity holders of the Company $ 128,484 $ 105,146 Loss attributable to equity holders of the Company, after deducting dividend accumulated for preferred shares $ 128,484 $ 105,146 Weighted-average number of ordinary shares 21,780,826 20,528,727 Loss per ordinary share $ 5.90 $ 5.12
Recently Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements In June 2016, the Financial Accounting Standards Board, or FASB, issued Accounting Standards Update, or ASU, No. 2016-13, Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments, or ASU 2016-13. ASU 2016-13 requires the Company to measure and recognize expected credit losses for certain financial instruments, including trade receivables, as an allowance that reflects the Company’s current estimate of credit losses expected to be incurred. For available-for-sale debt securities with unrealized losses, the standard requires allowances to be recorded through net income instead of directly reducing the amortized cost of the investment under the prior other-than-temporary impairment model. The Company applied the modified retrospective transition method as of the date of initial application, January 1, 2020. As of December 31, 2020, the Company believes the cost basis for its marketable securities were recoverable in all material aspects and no credit impairments were recognized in the period. Similarly, the Company estimates minimal current expected credit losses on trade receivables and has not recognized any allowance for doubtful accounts in the period.

Significant Accounting Polici_3

Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
Property and Equipment Useful Lives	Property and equipment are depreciated over the following useful lives (in years): Useful Lives Computers and software 3 Laboratory equipment 3-6.5 Furniture 5-16.5 Manufacturing equipment 2
Schedule of Calculation of Basic and Diluted Loss Per Share	The following table summarizes the calculation of basic and diluted loss per common share for the periods presented (in thousands, except share and per share amounts): Year Ended December 31, 2020 2019 Basic and diluted: Loss attributable to equity holders of the Company $ 128,484 $ 105,146 Loss attributable to equity holders of the Company, after deducting dividend accumulated for preferred shares $ 128,484 $ 105,146 Weighted-average number of ordinary shares 21,780,826 20,528,727 Loss per ordinary share $ 5.90 $ 5.12

Other Financial Information (Ta

Other Financial Information (Tables)	12 Months Ended
	Dec. 31, 2020
Other Financial Information [Abstract]
Schedule of Accounts Payable and Accrued Expenses	Accounts payable and accrued expenses consist of the following as of December 31, 2020 and 2019 (in thousands): December 31, 2020 December 31, 2019 Accounts payable $ 3,271 $ 4,694 Accrued sales reserves 382 — Accrued clinical expenses 1,359 399 Accrued research and development costs 1,356 2,644 Accrued general and administrative expenses 2,440 2,767 Accrued other expense 1,215 682 Total accrued expenses and other current liabilities $ 10,023 $ 11,186
Schedule of Interest and Other Income (Expenses)	Interest and other income (expenses) consisted of the following as of December 31, 2020 and 2019 (in thousands): Year Ended December 31, 2020 2019 Interest income 1,986 4,616 Other finance expenses (357 ) (284 ) Total interest and other income $ 1,629 $ 4,332

Inventories (Tables)

Inventories (Tables)	12 Months Ended
	Dec. 31, 2020
Inventory Disclosure [Abstract]
Summary of Inventories	Inventories consist of the following as of December 31, 2020 and December 31, 2019 (in thousands): December 31, 2020 December 31, 2019 Raw materials $ 1,051 — Finished goods 913 — Total inventories $ 1,964 $ —

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2020
Fair Value Disclosures [Abstract]
Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis	Assets and liabilities measured at fair value on a recurring basis based on Level 1 and Level 2 fair value measurement criteria as of December 31, 2020 are as follows (in thousands): Fair Value Measurements Using Quoted Prices Significant in Active Other Balance as of Markets for Observable December 31, Identical Assets Inputs 2020 (Level 1) (Level 2) Marketable securities: US government $ 29,186 $ 29,186 $ — Corporate bonds 21,861 — 21,861 Money market funds (1) 39,744 39,744 — Total marketable securities $ 90,791 $ 68,930 $ 21,861 (1) Included within cash and cash equivalents on the Company s consolidated balance sheets. Assets and liabilities measured at fair value on a recurring basis based on Level 1 and Level 2 fair value measurement criteria as of December 31, 2019 are as follows (in thousands): Fair Value Measurements Using Quoted Prices Significant in Active Other Balance as of Markets for Observable December 31, Identical Assets Inputs 2019 (Level 1) (Level 2) Marketable securities: US government $ 66,094 $ 66,094 $ — Corporate bonds 68,084 — 68,084 Commercial paper 7,658 — 7,658 Money market funds (1) 16,998 16,998 — Certificates of deposit 4,108 — 4,108 Total marketable securities $ 162,942 $ 83,092 $ 79,850 (1) Included within cash and cash equivalents on the Company s consolidated balance sheets.

Marketable Securities (Tables)

Marketable Securities (Tables)	12 Months Ended
	Dec. 31, 2020
Investments Debt And Equity Securities [Abstract]
Summary of Marketable Securities	The following table summarizes the Company’s marketable securities as of December 31, 2020 (in thousands): Amortized Cost Basis Unrealized Gains Fair Value Marketable securities: US government $ 28,970 $ 216 $ 29,186 Corporate bonds 21,806 55 21,861 Money market funds (1) 39,744 — 39,744 Total marketable securities $ 90,520 $ 271 $ 90,791 (1) Included within cash and cash equivalents on the Company s consolidated balance sheets.
Summary of Fair Values of Marketable Securities by Contractual Maturity	The fair values of marketable securities by contractual maturity consist of the following (in thousands): December 31, 2020 December 31, 2019 Maturities within one year $ 88,898 $ 114,386 Maturities after one year through three years 1,893 48,556 Total marketable securities $ 90,791 $ 162,942

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2020
Property Plant And Equipment [Abstract]
Schedule of Property and Equipment	Property and equipment, consists of the following as of December 31, 2020 and 2019 (in thousands): December 31, 2020 2019 Laboratory equipment $ 333 $ 259 Computer equipment and software 1,676 416 Furniture 597 544 Leasehold improvements 609 530 Manufacturing equipment 226 226 3,441 1,975 Less: accumulated depreciation and amortization (1,395 ) (998 ) Property and equipment, net $ 2,046 $ 977

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 31, 2020
Leases [Abstract]
Components of Lease Cost	The components of lease cost for the year ended December 31, 2020 were as follows (in thousands) Year Ended December 31, 2020 Operating lease cost $ 1,812 Sublease income (224 ) Variable lease cost 129 $ 1,717
Schedule of Amounts Recognized	The amounts recognized as of December 31, 2020 were as follows (in thousands): December 31, 2020 Right of use asset $ 2,158 Long-term lease liability 1,497 Other current liabilities 1,202
Schedule of Supplemental Information Related to Leases	Supplemental information related to leases for the periods reported is as follows (in thousands): Year Ended December 31, 2020 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases 1,726 Right-of-use assets obtained in exchange for new operating lease liabilities 135 Weighted-average remaining lease term of operating leases 2.26 years Weighted-average discount rate of operating leases 5.38%
Schedule of Maturities of Lease Liabilities	As of December 31, 2020, maturities of lease liabilities were as follows (in thousands): Operating Leases Years ending December 31, 2021 $ 1,307 2022 1,150 2023 357 2024 58 2025 and thereafter — Total future minimum lease payments $ 2,872 Less: Interest (173 ) Present value of lease liabilities $ 2,699
Schedule of Maturities of Lease Liabilities	As of December 31, 2019, maturities of lease liabilities were as follows (in thousands): Operating Leases Years ending December 31, 2020 $ 1,758 2021 1,269 2022 1,101 2023 348 2024 and thereafter 58 Total future minimum lease payments $ 4,534
Schedule of Undiscounted Cash Flows to be Received Under Operating Sublease on an Annual Basis	As of December 31, 2020, undiscounted cash flows to be received under the Company’s operating sublease on an annual basis was as follows (in thousands): Operating Leases Years ending December 31, 2021 $ 235 2022 243 2023 251 2024 49 2025 and thereafter — Total future minimum sublease payments $ 778
Schedule of Sublease Income Recognized Net within Operating Expenses	Sublease income is recognized net within operating expenses. Sublease income for the year ended December 31, 2020 was as follows (in thousands): Year Ended December 31, 2020 Sublease income from fixed lease payments $ 224

Revenue from Product Sales (Tab

Revenue from Product Sales (Tables)	12 Months Ended
	Dec. 31, 2020
Revenue From Contract With Customer [Abstract]
Schedule of Net Product Sales	Net product sales consist of the following for the year ended December 31, 2020 and 2019 (in thousands): Year Ended December 31, 2020 December 31, 2019 Jelmyto $ 11,799 $ —

Share-Based Compensation (Table

Share-Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2020
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Schedule of Fair Value of Options Granted	The e 2020 2019 Value of ordinary shares $16.50-29.41 $33.21-47.57 Dividend yield 0% 0% Expected volatility 71.43%-79.80% 74.09%-80.52% Risk-free interest rate 0.37%-1.35% 1.36%-2.62% Expected term 5.9-10 years 5.8-10 years
Summary of Number of Employee and Non-employee Options Outstanding Under the Plan	The employee and non-employee o b a Number of options Weighted Average price per share Outstanding as of January 1, 2019 2,522,981 $ 26.16 Granted 955,732 41.96 Canceled/Forfeited (183,725 ) 41.85 Exercised (423,653 ) 9.10 Outstanding as of December 31, 2019 2,871,335 $ 32.93 Granted 400,600 24.33 Canceled/Forfeited (408,534 ) 44.68 Exercised (137,070 ) 5.40 Outstanding as of December 31, 2020 2,726,331 $ 31.29
Summary of Number of Options Outstanding and Exercisable	The i Options outstanding Options exercisable Exercise price per share Number of options outstanding at end of year Weighted average remaining contractual life Number of options exercisable at end of year Weighted average remaining contractual life $0.00 - 10.00 588,324 1.99 588,324 1.99 $10.01 - 20.00 268,000 8.77 75,000 6.39 $20.01 - 30.00 272,800 8.19 139,999 7.24 $30.01 - 40.00 413,500 6.72 340,833 6.36 $40.01 - 50.00 1,063,041 7.17 771,250 6.93 $50.01 - 59.23 120,666 7.00 115,332 6.98 2,726,331 2,030,738
Summary of Information about RSU Activity	The following table summarizes information about RSU activity as of December 31, 2020: Outstanding Restricted Stock Units Outstanding as of January 1, 2019 263,699 Granted 455,465 Vested and released (183,975 ) Forfeited (15,762 ) Outstanding as of December 31, 2019 519,427 Granted 591,480 Vested and released (304,537 ) Forfeited (85,954 ) Outstanding as of December 31, 2020 720,416
Schedule of Effect of Share-Based Compensation on Statements of Operations	The p Year ended December 31, 2020 2019 Research and development expenses $ 6,432 $ 8,291 Selling, general and administrative expenses 21,593 21,676 Total share-based compensation expense $ 28,025 $ 29,967

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Schedule of Expense for Current Income Taxes	For financial reporting purposes, the expense for current income taxes consists of the following: 2020 2019 Current taxes: U.S. Federal $ 3,218 - U.S. State 156 - Total current taxes $ 3,374 -
Schedule of Deferred Income Taxes	Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company and its subsidiary deferred tax assets are as follows: December 31, 2020 2019 In respect of: Net operating loss carryforward $ 57,607 $ 33,817 Research and development expenses 5,362 4,591 Stock-based compensation 9,278 6,543 Issuance costs 978 2,063 In-process research and development 2,329 2,749 Right of use asset (372 ) (800 ) Lease Liability 473 896 Accrued expenses 1,589 762 Depreciation of fixed assets (299 ) (90 ) Other 18 62 Less—valuation allowance (76,963 ) (50,593 ) Net deferred tax assets $ — $ —
Schedule of Change in Valuation Allowance	The change in valuation allowance for the years ended December 31, 2020 and 2019 were as follows: 2020 2019 Balance at the beginning of the year $ (50,593 ) $ (28,249 ) Changes during the year (26,370 ) (22,344 ) Balance at the end of the year $ (76,963 ) $ (50,593 )
Reconciliation of Statutory Tax Rate to Effective Tax	A reconciliation of the Company’s statutory tax rate to effective tax is as follows: December 31, 2020 2019 Pretax income $ (125,110 ) $ (105,146 ) Statutory rate 23% 23% Income tax expense/(benefit) at statutory rate (28,775 ) (24,184 ) Additional tax (tax saving) in respect of: Non-deductible expenses 1,439 2,076 Different tax rate of foreign subsidiaries 17 20 Uncertain tax positions 2,717 - Change in valuation allowance 26,370 22,344 Other 1,607 (257 ) Income tax expense $ 3,374 $ -
Reconciliation of Uncertain Tax Positions	A reconciliation of the beginning and ending amount of uncertain tax positions is as follows: 2020 2019 Uncertain tax positions at the beginning of the year - - Gross increases — tax positions in current period 2,717 - Gross increases — tax positions in prior period - - Uncertain tax positions at the end of the year 2,717 -

Business and Nature of Operat_2

Business and Nature of Operations - Additional Information (Details)	12 Months Ended
	Dec. 31, 2020
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Date of incorporation	2004-04
Date of operating commencement	2016-02

Basis of Presentation - Additit

Basis of Presentation - Addititonal Information (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Accumulated deficit	$ 356,501	$ 228,017

Significant Accounting Polici_4

Significant Accounting Policies - Property and Equipment Useful Lives (Details)	12 Months Ended
	Dec. 31, 2020
Computers and Software
Property Plant And Equipment [Line Items]
Property and Equipment, Useful Lives	3 years
Laboratory Equipment | Minimum
Property Plant And Equipment [Line Items]
Property and Equipment, Useful Lives	3 years
Laboratory Equipment | Maximum
Property Plant And Equipment [Line Items]
Property and Equipment, Useful Lives	6 years 6 months
Furniture | Minimum
Property Plant And Equipment [Line Items]
Property and Equipment, Useful Lives	5 years
Furniture | Maximum
Property Plant And Equipment [Line Items]
Property and Equipment, Useful Lives	16 years 6 months
Manufacturing Equipment
Property Plant And Equipment [Line Items]
Property and Equipment, Useful Lives	2 years

Significant Accounting Polici_5

Significant Accounting Policies - Schedule of Calculation of Basic and Diluted Loss per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Basic and diluted:
Loss attributable to equity holders of the Company	$ 128,484	$ 105,146
Loss attributable to equity holders of the Company, after deducting dividend accumulated for preferred shares	$ 128,484	$ 105,146
Weighted-average number of ordinary shares	21,780,826	20,528,727
Loss per ordinary share	$ 5.90	$ 5.12

Significant Accounting Polici_6

Significant Accounting Policies - Additional Information (Details) - ASU 2016-13	Dec. 31, 2020
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
Change in Accounting Principle, Accounting Standards Update, Adopted [true false]	true
Change in Accounting Principle, Accounting Standards Update, Adoption Date	Jan. 1, 2020
Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]	false

Other Financial Information - S

Other Financial Information - Schedule of Accounts Payable and Accrued Expenses (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Other Financial Information [Abstract]
Accounts payable	$ 3,271	$ 4,694
Accrued sales reserves	382
Accrued clinical expenses	1,359	399
Accrued research and development costs	1,356	2,644
Accrued general and administrative expenses	2,440	2,767
Accrued other expense	1,215	682
Total accrued expenses and other current liabilities	$ 10,023	$ 11,186

Other Financial Information -_2

Other Financial Information - Schedule of Interest and Other Income (Expenses) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Other Financial Information [Abstract]
Interest income	$ 1,986	$ 4,616
Other finance expenses	(357)	(284)
Total interest and other income	$ 1,629	$ 4,332

Inventories - Schedule of Inven

Inventories - Schedule of Inventories (Details) $ in Thousands	Dec. 31, 2020USD ($)
Inventory Disclosure [Abstract]
Raw materials	$ 1,051
Finished goods	913
Total inventories	$ 1,964

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Details)	12 Months Ended
	Dec. 31, 2020USD ($)
Fair Value Disclosures [Abstract]
Fair value assets, transfers between level 1 to level 2	$ 0
Fair value assets, transfers between level 2 to level 1	0
Fair value liabilities, transfers between level 1 to level 2	0
Fair value liabilities, transfers between level 2 to level 1	0
Fair value assets, transfers into level 3	0
Fair value assets, transfers out of level 3	0
Fair value liabilities, transfers into level 3	0
Fair value liabilities, transfers out of level 3	$ 0

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Marketable securities:	$ 90,791	$ 162,942
Fair Value, Measurements, Recurring
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Marketable securities:	90,791	162,942
Fair Value, Measurements, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Marketable securities:	68,930	83,092
Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2)
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Marketable securities:	21,861	79,850
Fair Value, Measurements, Recurring | US Government
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Marketable securities:	29,186	66,094
Fair Value, Measurements, Recurring | US Government | Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Marketable securities:	29,186	66,094
Fair Value, Measurements, Recurring | Corporate Bonds
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Marketable securities:	21,861	68,084
Fair Value, Measurements, Recurring | Corporate Bonds | Significant Other Observable Inputs (Level 2)
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Marketable securities:	21,861	68,084
Fair Value, Measurements, Recurring | Commercial Paper
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Marketable securities:		7,658
Fair Value, Measurements, Recurring | Commercial Paper | Significant Other Observable Inputs (Level 2)
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Marketable securities:		7,658
Fair Value, Measurements, Recurring | Money Market Funds
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Marketable securities:	39,744	16,998
Fair Value, Measurements, Recurring | Money Market Funds | Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Marketable securities:	$ 39,744	16,998
Fair Value, Measurements, Recurring | Certificates of Deposit
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Marketable securities:		4,108
Fair Value, Measurements, Recurring | Certificates of Deposit | Significant Other Observable Inputs (Level 2)
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Marketable securities:		$ 4,108

Marketable Securities - Summary

Marketable Securities - Summary of Marketable Securities (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Marketable securities:
Amortized Cost Basis	$ 90,520
Unrealized Gains	271
Fair Value	90,791	$ 162,942
US Government
Marketable securities:
Amortized Cost Basis	28,970
Unrealized Gains	216
Fair Value	29,186
Corporate Bonds
Marketable securities:
Amortized Cost Basis	21,806
Unrealized Gains	55
Fair Value	21,861
Money Market Funds
Marketable securities:
Amortized Cost Basis	39,744
Fair Value	$ 39,744

Marketable Securities - Additio

Marketable Securities - Additional Information (Details)	12 Months Ended
	Dec. 31, 2020USD ($)
Investments Debt And Equity Securities [Abstract]
Available-for-sale debt securities, unrealized gain position	$ 300,000
Available-for-sale debt securities, unrealized loss position	0
Other-than-temporary impairment Loss, debt securities, portion recognized in earnings	$ 0

Marketable Securities - Summa_2

Marketable Securities - Summary of Fair Values of Marketable Securities by Contractual Maturity (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Available For Sale Securities Debt Maturities Fair Value [Abstract]
Maturities within one year	$ 88,898	$ 114,386
Maturities after one year through three years	1,893	48,556
Total marketable securities	$ 90,791	$ 162,942

Property and Equipment - Schedu

Property and Equipment - Schedule of Property and Equipment (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Property Plant And Equipment [Line Items]
Property and equipment	$ 3,441	$ 1,975
Less: accumulated depreciation and amortization	(1,395)	(998)
Property and equipment, net	2,046	977
Laboratory Equipment
Property Plant And Equipment [Line Items]
Property and equipment	333	259
Computers and Software
Property Plant And Equipment [Line Items]
Property and equipment	1,676	416
Furniture
Property Plant And Equipment [Line Items]
Property and equipment	597	544
Leasehold Improvements
Property Plant And Equipment [Line Items]
Property and equipment	609	530
Manufacturing Equipment
Property Plant And Equipment [Line Items]
Property and equipment	$ 226	$ 226

Property and Equipment - Additi

Property and Equipment - Additional Information (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Property Plant And Equipment [Abstract]
Depreciation and amortization expense	$ 0.4	$ 0.3

Leases - Additional Information

Leases - Additional Information (Details) - USD ($) $ in Thousands	1 Months Ended		12 Months Ended
	Nov. 30, 2019	Apr. 30, 2018	Dec. 31, 2020
Lessee Lease Description [Line Items]
Operating leases, existence of option to extend			true
Operating leases, options to extend lease term, description			UPL signed an addendum to its November 2014 lease agreement for the Company’s executive offices located in Israel, in order to increase the office space rented and to extend the rent period until 2019. In March 2019, UPL exercised the agreement extension option and extended the rental period for an additional three years until August 2022.
Operating leases, options to extend lease term			3 years
Operating lease extended lease expiration, month and year			2022-08
Remaining rental payments to be received over the lease term			$ 224
Minimum
Lessee Lease Description [Line Items]
Lease expiration year			2021
Maximum
Lessee Lease Description [Line Items]
Lease expiration year			2023
New York
Lessee Lease Description [Line Items]
Impairment losses on operating leases			$ 200
New York | UroGen Pharma Inc.
Lessee Lease Description [Line Items]
Lease commencement period, month and year			2017-10
Lease termination period, month and year			2021-02
Los Angeles, California | UroGen Pharma Inc.
Lessee Lease Description [Line Items]
Lease termination period, month and year		2024-03
Lease commencement date		Jul. 10, 2018
Proceeds from tenant allowance		$ 200
Remaining contractual obligation			$ 900
Lessee operating sublease commencement date	Jan. 1, 2020
Lessee operating sublease termination period, month and year	2024-03
Remaining rental payments to be received over the lease term			700
Princeton, NJ | UroGen Pharma Inc. | Lease Agreement
Lessee Lease Description [Line Items]
Lease commencement date	Nov. 29, 2019
Remaining contractual obligation			$ 1,200
Lease term	38 months

Leases - Components of Lease Co

Leases - Components of Lease Cost (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2020USD ($)
Leases [Abstract]
Operating lease cost	$ 1,812
Sublease income	(224)
Variable lease cost	129
Lease, Cost	$ 1,717

Leases - Schedule of Amounts Re

Leases - Schedule of Amounts Recognized (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Leases [Abstract]
Right of use asset	$ 2,158	$ 3,735
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]	us-gaap:OtherAssetsNoncurrent
Long-term lease liability	$ 1,497	$ 2,604
Other current liabilities	$ 1,202
Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]	us-gaap:OtherLiabilitiesCurrent

Leases - Schedule of Supplement

Leases - Schedule of Supplemental Information Related to Leases (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2020USD ($)
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$ 1,726
Right-of-use assets obtained in exchange for new operating lease liabilities	$ 135
Weighted-average remaining lease term of operating leases	2 years 3 months 3 days
Weighted-average discount rate of operating leases	5.38%

Leases - Schedule of Maturities

Leases - Schedule of Maturities of Lease Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Leases [Abstract]
2021	$ 1,307
2022	1,150
2023	357
2024	58
Total future minimum lease payments	2,872
Less: Interest	(173)
Present value of lease liabilities	$ 2,699
2020		$ 1,758
2021		1,269
2022		1,101
2023		348
2024 and thereafter		58
Total future minimum lease payments		$ 4,534

Leases - Schedule of Undiscount

Leases - Schedule of Undiscounted Cash Flows to be Received Under Operating Sublease on an Annual Basis (Details) $ in Thousands	Dec. 31, 2020USD ($)
Leases [Abstract]
2021	$ 235
2022	243
2023	251
2024	49
Total future minimum sublease payments	$ 778

Leases - Schedule of Sublease I

Leases - Schedule of Sublease Income Recognized Net within Operating Expenses (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2020USD ($)
Leases [Abstract]
Sublease income from fixed lease payments	$ 224

Revenue from Product Sales - Sc

Revenue from Product Sales - Schedule of Net Product Sales (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Revenue From Contract With Customer [Abstract]
Revenue From Contract With Customer Product And Service [Extensible List]	urgn:Jelmyto1Member	urgn:Jelmyto1Member
Revenues, net	$ 11,799	$ 18

License and Collaboration Agr_2

License and Collaboration Agreements - Additional Information (Details) - USD ($)	1 Months Ended	12 Months Ended
	Nov. 30, 2019	Dec. 31, 2020	Dec. 31, 2019
Agenus Agreement
Research And Development Arrangement Contract To Perform For Others [Line Items]
Upfront fee	$ 10,000,000
Maximum amount payable upon achieving certain clinical development and regulatory milestones	115,000,000
Maximum amount payable upon achieving certain commercial milestones	$ 85,000,000
License agreement milestone in acquired in-process research and development expenses			$ 10,000,000
Agenus Agreement | After First Commercial Sale of Licensed Product
Research And Development Arrangement Contract To Perform For Others [Line Items]
License agreement expiration term	15 years
Maximum | Agenus Agreement
Research And Development Arrangement Contract To Perform For Others [Line Items]
Royalty ranging on net sales of licensed products	20.00%
Minimum | Agenus Agreement
Research And Development Arrangement Contract To Perform For Others [Line Items]
Royalty ranging on net sales of licensed products	14.00%
Allergan/AbbVie | License Agreement
Research And Development Arrangement Contract To Perform For Others [Line Items]
Milestone payments received for licensing agreement		$ 25,000,000
Allergan/AbbVie | License Agreement | Maximum
Research And Development Arrangement Contract To Perform For Others [Line Items]
License agreement additional milestone payments eligible to receive		$ 200,000,000

Shareholders' Equity - Addition

Shareholders' Equity - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended		3 Months Ended	12 Months Ended
	Dec. 31, 2019	Jan. 31, 2019	Jun. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Class Of Stock [Line Items]
Ordinary shares, shares authorized	100,000,000			100,000,000	100,000,000
Ordinary shares, issued	21,026,184			22,167,791	21,026,184
Ordinary shares, outstanding	21,026,184			22,167,791	21,026,184
Issuance of ordinary shares, consideration received net of underwriting discounts and commissions and issuance costs				$ 15,777	$ 161,447
Issuance of ordinary shares, net of issuance expenses				$ 15,853	$ 161,662
Cowen and Company Limited Liability Company | ATM Sales Agreement
Class Of Stock [Line Items]
Issuance of ordinary shares, shares			700,000
Issuance of ordinary shares, net of issuance expenses			$ 16,600
Net proceeds from issuance ordinary shares after deducting sales commissions			15,800
Issuance of ordinary shares, value, remaining capacity			$ 83,400
Cowen and Company Limited Liability Company | ATM Sales Agreement | Maximum
Class Of Stock [Line Items]
Issuance of ordinary shares, consideration received net of underwriting discounts and commissions and issuance costs	$ 100,000
Underwritten Public Offering
Class Of Stock [Line Items]
Issuance of ordinary shares, shares		4,207,317
Additional ordinary shares exercised under underwriters option to purchase at the public offering price		548,780
Issuance of ordinary shares, price per share		$ 41
Issuance of ordinary shares, consideration received net of underwriting discounts and commissions and issuance costs		$ 161,400

Share-Based Compensation - Addi

Share-Based Compensation - Additional Information (Details)	Jun. 08, 2020shares	Jan. 03, 2019USD ($)$ / sharesshares	Oct. 12, 2018shares	Jan. 01, 2018shares	Jun. 30, 2020USD ($)$ / sharesshares	Dec. 31, 2019USD ($)	Jun. 30, 2019USD ($)$ / sharesshares	Mar. 31, 2017shares	Dec. 31, 2020USD ($)$ / sharesshares	Dec. 31, 2019USD ($)$ / sharesshares	May 31, 2019shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options granted | shares									400,600	955,732
Share-based compensation									$ 28,025,000	$ 29,967,000
Stock option exercise prices ranging lower limit | $ / shares									$ 16.50	$ 33.21
Stock option exercise prices ranging upper limit | $ / shares									$ 29.41	$ 47.57
Fair value of option granted									$ 6,700,000	$ 27,600,000
Unrecognized compensation cost of employee options									$ 13,500,000
Expected to be recognized over a weighted average period									1 year 4 months 13 days
Intrinsic value of stock options exercised									$ 2,300,000	14,200,000
Aggregate intrinsic value of the total vested and exercisable options									$ 7,700,000
Options | General and Administrative Expenses
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation						$ 900,000
Options | Elizabeth Barrett
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Option to purchase of ordinary shares | shares		277,432
Exercise price of option to purchase of ordinary shares | $ / shares		$ 47.57
Options | Non-employee Directors
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options granted, expected term					10 years		10 years
Awards vesting period					1 year		1 year
Number of stock options approved for grants | shares					70,000		70,000
Stock options granted | shares					10,000		10,000
Exercise of option to ordinary shares conversion ratio					1		1
Stock option exercise | $ / shares					$ 28.24		$ 34.83
Estimated fair value of options granted					$ 1,500,000		$ 1,900,000
Options | Chairman of Board of Directors
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options granted | shares					10,000		10,000
Options | Tranche One
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting percentage									33.00%
Restricted Stock Units (RSUs)
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Awards vesting period									2 years
Share-based compensation						$ 0
Expected to be recognized over a weighted average period									1 year 10 months 2 days
Fair value of RSUs granted									$ 15,600,000	$ 19,900,000
Unrecognized compensation cost of RSUs									$ 17,600,000
Restricted Stock Units (RSUs) | Elizabeth Barrett
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Option to purchase of ordinary shares | shares		317,065
Restricted Stock Units (RSUs) | Tranche One
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting percentage									33.00%
2017 Equity Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Maximum number of ordinary share issuable under the 2017 incentive plan | shares								1,400,000	5,600,000
Number of ordinary shares reserved for issuance, percentage									12.00%
Increase in number of ordinary share issuable under the 2017 incentive plan | shares	400,000		1,900,000	250,167
Stock Options and Restricted Stock Units (RSUs) | Elizabeth Barrett
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Fair value		$ 24,100,000
Plan | Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Awards vesting period									3 years
Combined voting power percentage									10.00%
Ordinary Shares | 2019 Inducement Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of stock options approved for grants | shares											900,000
Ordinary Shares | 2017 Equity Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Maximum number of ordinary share issuable under the 2017 incentive plan | shares	3,950,167		3,550,167	1,650,167
Maximum | Plan | Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options granted, expected term									10 years
Minimum | Plan | Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Exercise price of stock options as percentage of fair market value of shares on grant date									100.00%
Stock options exercise price percentage for individuals possesses more than 10% of the combined voter power									110.00%

Share Based Compensation - Sche

Share Based Compensation - Schedule of Fair Value of Options Granted (Details) - Options - $ / shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Dividend yield	0.00%	0.00%
Expected volatility, Minimum	71.43%	74.09%
Expected volatility, Maximum	79.80%	80.52%
Risk-free interest rate, Minimum	0.37%	1.36%
Risk-free interest rate, Maximum	1.35%	2.62%
Minimum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Value of ordinary shares	$ 16.5	$ 33.21
Expected term	5 years 10 months 24 days	5 years 9 months 18 days
Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Value of ordinary shares	$ 29.41	$ 47.57
Expected term	10 years	10 years

Share Based Compensation - Summ

Share Based Compensation - Summary of Number of Employee and Non-employee Options Outstanding Under the Plan (Details) - $ / shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Options, Granted	400,600	955,732
Employees and Non-employees
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Options, Outstanding beginning balance	2,871,335	2,522,981
Number of Options, Granted	400,600	955,732
Number of Options, Canceled/Forfeited	(408,534)	(183,725)
Number of Options, Exercised	(137,070)	(423,653)
Number of Options, Outstanding ending balance	2,726,331	2,871,335
Weighted Average Price Per Share, Outstanding beginning balance	$ 32.93	$ 26.16
Weighted Average Price Per Share, Granted	24.33	41.96
Weighted Average Price Per Share, Canceled/Forfeited	44.68	41.85
Weighted Average Price Per Share, Exercised	5.40	9.10
Weighted Average Price Per Share, Outstanding ending balance	$ 31.29	$ 32.93

Share Based Compensation - Su_2

Share Based Compensation - Summary of Number of Options Outstanding and Exercisable (Details) - $ / shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options outstanding, exercise price per share	$ 16.50	$ 33.21
Options outstanding, exercise price per share	$ 29.41	$ 47.57
Options outstanding, number of options outstanding at end of year	2,726,331
Options exercisable, number of options outstanding at end of year	2,030,738
0.00 - 10.00
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options outstanding, exercise price per share	$ 0
Options outstanding, exercise price per share	$ 10
Options outstanding, number of options outstanding at end of year	588,324
Options outstanding, weighted average remaining contractual life	1 year 11 months 26 days
Options exercisable, number of options outstanding at end of year	588,324
Options exercisable, weighted average remaining contractual life	1 year 11 months 26 days
10.01 - 20.00
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options outstanding, exercise price per share	$ 10.01
Options outstanding, exercise price per share	$ 20
Options outstanding, number of options outstanding at end of year	268,000
Options outstanding, weighted average remaining contractual life	8 years 9 months 7 days
Options exercisable, number of options outstanding at end of year	75,000
Options exercisable, weighted average remaining contractual life	6 years 4 months 20 days
20.01 - 30.00
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options outstanding, exercise price per share	$ 20.01
Options outstanding, exercise price per share	$ 30
Options outstanding, number of options outstanding at end of year	272,800
Options outstanding, weighted average remaining contractual life	8 years 2 months 8 days
Options exercisable, number of options outstanding at end of year	139,999
Options exercisable, weighted average remaining contractual life	7 years 2 months 26 days
30.01 - 40.00
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options outstanding, exercise price per share	$ 30.01
Options outstanding, exercise price per share	$ 40
Options outstanding, number of options outstanding at end of year	413,500
Options outstanding, weighted average remaining contractual life	6 years 8 months 19 days
Options exercisable, number of options outstanding at end of year	340,833
Options exercisable, weighted average remaining contractual life	6 years 4 months 9 days
40.01 - 50.00
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options outstanding, exercise price per share	$ 40.01
Options outstanding, exercise price per share	$ 50
Options outstanding, number of options outstanding at end of year	1,063,041
Options outstanding, weighted average remaining contractual life	7 years 2 months 1 day
Options exercisable, number of options outstanding at end of year	771,250
Options exercisable, weighted average remaining contractual life	6 years 11 months 4 days
50.01 - 59.23
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options outstanding, exercise price per share	$ 50.01
Options outstanding, exercise price per share	$ 59.23
Options outstanding, number of options outstanding at end of year	120,666
Options outstanding, weighted average remaining contractual life	7 years
Options exercisable, number of options outstanding at end of year	115,332
Options exercisable, weighted average remaining contractual life	6 years 11 months 23 days

Share Based Compensation - Su_3

Share Based Compensation - Summary of Information about RSU Activity (Details) - Restricted Stock Units (RSUs) - shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Options, Outstanding beginning balance	519,427	263,699
Granted	591,480	455,465
Vested and released	(304,537)	(183,975)
Forfeited	(85,954)	(15,762)
Number of Options, Outstanding ending balance	720,416	519,427

Share Based Compensation - Sc_2

Share Based Compensation - Schedule of Effect of Share-Based Compensation on Statements of Operations (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation	$ 28,025	$ 29,967
Research and Development Expenses
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation	6,432	8,291
Selling, General and Administrative Expenses
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation	$ 21,593	$ 21,676

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Corporate tax rate	23.00%	23.00%	23.00%
Net carryforward tax losses	$ 250,200	$ 151,900
Liabilities for uncertain tax positions	2,717
Accrued interest and penalties related to uncertain tax positions	$ 700

Income Taxes - Schedule of Expe

Income Taxes - Schedule of Expense for Current Income Taxes (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2020USD ($)
Current taxes:
U.S. Federal	$ 3,218
U.S. State	156
Total current taxes	$ 3,374

Income Taxes - Schedule of Defe

Income Taxes - Schedule of Deferred Income Taxes (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
In respect of:
Net operating loss carryforward	$ 57,607	$ 33,817
Research and development expenses	5,362	4,591
Stock-based compensation	9,278	6,543
Issuance costs	978	2,063
In-process research and development	2,329	2,749
Right of use asset	(372)	(800)
Lease Liability	473	896
Accrued expenses	1,589	762
Depreciation of fixed assets	(299)	(90)
Other	18	62
Less—valuation allowance	$ (76,963)	$ (50,593)	$ (28,249)

Income Taxes - Schedule of Chan

Income Taxes - Schedule of Change in Valuation Allowance (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Valuation Allowance [Abstract]
Balance at the beginning of the year	$ (50,593)	$ (28,249)
Changes during the year	(26,370)	(22,344)
Balance at the end of the year	$ (76,963)	$ (50,593)

Income Taxes - Reconciliation o

Income Taxes - Reconciliation of Statutory Tax Rate to Effective Tax (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Income Tax Expense Benefit Continuing Operations Income Tax Reconciliation [Abstract]
Pretax income	$ (125,110)	$ (105,146)
Statutory rate	23.00%	23.00%	23.00%
Income tax expense/(benefit) at statutory rate	$ (28,775)	$ (24,184)
Non-deductible expenses	1,439	2,076
Different tax rate of foreign subsidiaries	17	20
Uncertain tax positions	2,717
Change in valuation allowance	26,370	22,344
Other	1,607	$ (257)
Income tax expense	$ 3,374

Income Taxes - Reconciliation_2

Income Taxes - Reconciliation of Uncertain Tax Positions (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2020USD ($)
Income Tax Disclosure [Abstract]
Gross increases — tax positions in current period	$ 2,717
Uncertain tax positions at the end of the year	$ 2,717

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2020	Mar. 31, 2020
Pfreundschuh
Commitments And Contingent Liabilities [Line Items]
Employee termination cost	$ 0.7
IIA
Commitments And Contingent Liabilities [Line Items]
Royalty amount payable		$ 6.6
Maximum percentage of commitment to continue employment of research and development jobs	75.00%
Maximum term for commitment to continue employment of research and development jobs	3 years

Subsequent Events - Additional

Subsequent Events - Additional Information (Details) - USD ($)	1 Months Ended
	Mar. 31, 2021	Jan. 31, 2021
MD Anderson | Subsequent Events
Subsequent Event [Line Items]
Upfront cash payments made		$ 500,000
RTW Investments | Scenario Forecast
Subsequent Event [Line Items]
Upfront fee	$ 75,000,000